Hikal Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook

Wed Apr 15 2026

Hikal (NSE: HIKAL) is set to announce its Q4 FY26 (January–March 2026) results on May 10, 2026. Trading at Rs 285 as of April 2026 — down -38% from its 52-week high of Rs 460 — the stock enters this pivotal results event having already corrected meaningfully from peak levels. Q4 FY26 delivers the full-year FY26 performance and the first formal FY27 management guidance.

This preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook for Hikal ahead of Q4 FY26 results.

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

Hikal Q4 Results 2026 Date

The Hikal Q4 FY26 results date is May 10, 2026. The board will approve Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management’s first formal FY27 business outlook.

Company	Q4 Results Date	Key Metric to Watch
TCS	April 9, 2026 (Declared)	FY27 CC guidance + deal TCV
Infosys	April 23, 2026	CC revenue growth range
HCL Technologies	April 22, 2026	CC growth + EBIT margin
HDFC Bank	April 19, 2026	NIM recovery + loan growth
Hikal	May 10, 2026	See estimates below

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025–26 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, the Hikal board on May 10, 2026 will deliver the complete FY26 annual performance, a final dividend recommendation, and the first formal FY27 guidance commentary — making this the single most important quarterly event for Hikal investors.

For Hikal in the Specialty Pharma Chemicals / CDMO sector, Q4 captures the peak-season demand dynamics that typically deliver the quarter’s strongest operating leverage when execution conditions are favourable.

Hikal Q4 FY26 Earnings Estimates

Hikal Q4 FY26 analyst estimates — Revenue Rs 520 Cr, PAT Rs 28 Cr | univest.in

Access premium analyst research on Univest.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 520 Cr	Rs 473 Cr	Sequential improvement expected
Net Profit (PAT)	Rs 28 Cr	Rs 25 Cr	Normalisation in progress
Operating Margin	EBITDA 12%	Q3 FY26 level	Stable to improving
Volume / Revenue Growth	+10% volume YoY	Prior quarter	YoY improvement expected
Final Dividend (Expected)	Rs 2	FY26 interim dividends	Board decision on May 10, 2026

Screen Hikal live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.

Download the Univest iOS App or Univest Android App for live Q4 result alerts.

5 Key Factors Driving Hikal Q4 FY26 Performance

1. India Branded Generic Growth

India pharmaceutical market growing at 8-10% annually. Q4 captures year-end prescription momentum.

2. US Generic Revenue

ANDA approvals and generic launches drive US export revenue. First-to-file paragraphs provide 180-day exclusivity.

3. CDMO Revenue

Contract manufacturing for global innovators provides long-term, high-margin revenue.

4. New Product Launches

New OTC and branded generic launches in India expand domestic market share.

5. API Cost Normalisation

Global API price moderation benefits formulation company gross margins.

5 Risks to Watch in Hikal Q4 FY26

Risk 1: Input Cost Volatility

Raw material and input cost changes can compress margins unexpectedly.

Risk 2: Revenue Concentration Risk

Customer or geographic concentration creates quarterly variance.

Risk 3: Competitive Pressure

Intensified sector competition may require price or volume concessions.

Risk 4: Regulatory Environment

Policy and regulatory changes can create compliance cost or revenue risks.

Risk 5: Macroeconomic Sensitivity

Global and domestic conditions — tariffs, interest rates, consumption — affect demand.

Hikal Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 285
52-Week High	Rs 460
52-Week Low	Rs 248
1-Year Return	-38%
Market Cap	Rs 2,800 Cr
Sector	Specialty Pharma Chemicals / CDMO
NSE Ticker	HIKAL
Q4 Results Date	May 10, 2026

Brokerage	Rating	Thesis Summary
Motilal Oswal	BUY	Q4 recovery potential; sector tailwinds intact
YES Securities	ADD	Earnings inflection expected; FY27 guidance key
Kotak Institutional	NEUTRAL	Fair valued at current levels; execution key

Conclusion

Hikal Q4 FY26 results on May 10, 2026 will be the most important quarterly event of FY26. At Rs 285 — down -38% from its 52-week high of Rs 460 — the stock has already priced in significant headwinds. Revenue above Rs 520 Cr with EBITDA 12% would constitute a beat versus analyst consensus. Management’s FY27 guidance is the primary re-rating catalyst that determines whether the current level represents an entry opportunity.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All data sourced from publicly available information. Verify before investing. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Hikal Q4 results 2026 date?

Hikal Q4 FY26 results date is May 10, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.

Q: What is Hikal Q4 FY26 revenue estimate?

Analyst consensus Q4 FY26 revenue estimate for Hikal is Rs 520 Cr. Q3 FY26 actual revenue was Rs 473 Cr. Actual results may differ based on operating conditions.

Q: What is Hikal share price ahead of Q4 results?

Hikal trades at Rs 285 as of April 2026. 52-week high is Rs 460; 52-week low is Rs 248. 1-year return is -38%. Market cap is Rs 2,800 Cr.

Q: Will Hikal declare a dividend in Q4 2026?

Hikal is expected to declare Rs 2 as final dividend for FY26, subject to board approval on May 10, 2026 and subsequent AGM shareholder approval.

Q: Which analysts have a Buy rating on Hikal?

Motilal Oswal has a BUY rating and YES Securities has an ADD rating on Hikal based on publicly available research. Check the Univest Screener for the latest analyst ratings.

Q: What were Hikal Q3 FY26 results?

Hikal reported Q3 FY26 revenue of Rs 473 Cr and PAT of Rs 25 Cr. The Q4 FY26 results on May 10, 2026 provide the full-year FY26 comparison and first FY27 guidance.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. HCL Technologies declared on April 22. HDFC Bank declared on April 19. Infosys Q4 FY26 results are scheduled for April 23, 2026.

Q: Is Hikal a good investment ahead of Q4 results?

This article does not constitute investment advice. Hikal trades at Rs 285 — down -38% from its peak. Analyst consensus Q4 revenue estimate is Rs 520 Cr and PAT estimate is Rs 28 Cr. Review the five factors and five risks above. Consult a SEBI-registered financial advisor before investing.